Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

VolitionRx Limited (NYSE:VNRX) insider Jacob Vincent Micallef purchased 50,000 shares of the stock in a transaction on Monday, May 19th. The shares were purchased at an average price of $0.43 per share, with a total value of $21,500.00. Following the acquisition, the insider now directly owns 426,033 shares in the company, valued at $183,194.19. This represents a 13.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

VolitionRx Trading Down 2.5%

Shares of VolitionRx stock opened at $0.42 on Tuesday. The company has a fifty day simple moving average of $0.51 and a 200-day simple moving average of $0.59. VolitionRx Limited has a 12-month low of $0.40 and a 12-month high of $0.90. The stock has a market cap of $42.24 million, a price-to-earnings ratio of -1.16 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. StockNews.com began coverage on VolitionRx in a report on Thursday, May 15th. They issued a “sell” rating on the stock. HC Wainwright initiated coverage on VolitionRx in a report on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price objective on the stock. Finally, D. Boral Capital reissued a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Wednesday, April 30th.

Institutional Investors Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently bought and sold shares of VNRX. Millennium Management LLC purchased a new position in shares of VolitionRx during the fourth quarter worth about $36,000. Lagoda Investment Management L.P. boosted its position in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the period. Northern Trust Corp boosted its position in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in VolitionRx during the 4th quarter worth approximately $29,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.